Hot-pe trial
WebMar 1, 2024 · The safety outcome of major bleeding was 1.2% in the Barco et al study and 0.7-1.8% in prior trials with warfarin. In previous trials of rivaroxaban in DVT, the major bleeding rates were 0.5-2.0%. Thus, efficacy and safety are similar to PE trials with warfarin and DVT studies with DOACs. WebDec 4, 2024 · Much more evidence is expected on short notice, notably for the HOME-PE study. In this randomized controlled noninferiority trial, 1975 normotensive PE patients are randomized to risk stratification by either the Hestia rule or the simplified PESI (sPESI) for determining the possibility of home treatment (#NCT02811237).
Hot-pe trial
Did you know?
WebMar 20, 2024 · Barco S, Schmidtmann I, Ageno W, et al; on behalf of the HoT-PE Investigators. Early discharge and home treatment of patients with low-risk pulmonary … WebNov 25, 2024 · Subgroup analyses of randomized trials and cohort studies on direct oral anticoagulants (DOACs) suggested that single direct drug treatment may be effective …
WebSep 27, 2016 · Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot … WebStudy design and participants. HoT-PE (EudraCT identifier 2013-001657-28) is a prospective multicentre single-arm investigator-initiated phase 4 interventional trial sponsored by the University Medical Center Mainz, Mainz, Germany [].The institutional Ethics Review Board of each participating site approved the study and patients provided …
WebPulmonary embolism is a common disease, with an estimated annual incidence of 70 cases per 100,000 population. 1,2 The condition usually leads to hospitalization and may recur; it can be fatal. 3 ... WebFeb 4, 2024 · Introduction: Early discharge of patients with acute low-risk pulmonary embolism requires validation by prospective trials with clinical and quality-of-life …
WebAug 31, 2024 · Patients with acute pulmonary embolism can be selected for home management using the sPESI score or the Hestia criteria, according to results of the HOME-PE trial presented in a Hot Line session ...
WebMar 24, 2016 · The HoT-PE Trial (home treatment of patients with low-risk PE with the oral factor Xa inhibitor rivaroxaban) is a prospective cohort study enrolling low risk PE patients (defined by the absence of ... campagne warhammer jdrWebPulmonary embolism is a common disease, with an estimated annual incidence of 70 cases per 100,000 population. 1,2 The condition usually leads to hospitalization and may recur; … campagne shot on iphoneWebJun 11, 2024 · However, most of these trials were small in size and included different methods for identification of risk. 27 In the recently presented HoT-PE trial, 525 patients … campagne bob hiverWebThe HoT-PE Trial 3 Male, 81 ≥ 1 Major bleedinga 20 mg once daily 57 12 Haemorrhagic shock following acute bleeding from intestinal diverticula. Red blood cell concentrates; rivaroxaban discontinuation and switch to LMWH. Subsequently, the patient suffered one further gastrointestinal major bleeding episode on heparin. first signal line of fire 評価WebHome treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban : Rationale and design of the HoT-PE Trial. / Barco, Stefano; Lankeit, Mareike; Binder, Harald et al. In: THROMBOSIS AND HAEMOSTASIS, Vol. 116, No. 1, 01.07.2016, p. 191-197. Research output: Contribution to journal › Article › peer-review first sight words to teach preschoolersfirst signal line of fireWebAug 31, 2024 · Sophia Antipolis, France – 31 Aug 2024: Patients with acute pulmonary embolism can be selected for home management using the sPESI score or the Hestia criteria, according to results of the HOME-PE trial presented in a Hot Line session today at ESC Congress 2024. 1. Principal investigator Professor Pierre-Marie Roy of the … campagne warhammer